Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia

European Neuropsychopharmacology

Volumn 24, Issue 8, 2014, Pages 1222-1228

  Knuts, Inge ^a   Esquivel, Gabriel ^a   Kenis, Gunter ^a   Overbeek, Thea ^a   Leibold, Nicole ^a   Goossens, Lies ^a   Schruers, Koen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Agoraphobia; Behavior therapy; Exposure therapy; Genetics; Panic disorder; Serotonin

Indexed keywords

5 HTT LINKED POLYMORPHIC REGION; ANTIDEPRESSANT AGENT; GENOMIC DNA; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; SLC6A4 PROTEIN, HUMAN;

ADULT; AGORAPHOBIA; ALLELE; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR THERAPY; CLINICAL GENETICS; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANIC; PRIORITY JOURNAL; PROMOTER REGION; THERAPYGENETICS; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; COMPLICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SOMATOFORM DISORDER;

ADULT; AGORAPHOBIA; ANALYSIS OF VARIANCE; FEMALE; GENE FREQUENCY; GENETIC TESTING; GENOTYPE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 84905051565     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.05.007     Document Type: Article

References (53)

1. Arias B., Catalan R., Gasto C., Gutierrez B., Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol. 2003, 23(6):563-567.
2. Bakker A., van Balkom A.J., Stein D.J. Evidence-based pharmacotherapy of panic disorder. Int. J. Neuropsychopharmacol. 2005, 8(3):473-482.
3. Bandelow B., Brunner E., Broocks A., Beinroth D., Hajak G., Pralle L., et al. The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res. 1998, 77(1):43-49.
4. Belsky J., Jonassaint C., Pluess M., Stanton M., Brummett B., Williams R. Vulnerability genes or plasticity genes?. Mol. Psychiatry 2009, 14(8):746-754.
5. Belsky J., Pluess M. Beyond diathesis stress: differential susceptibility to environmental influences. Psychol. Bull. 2009, 135(6):885-908.
6. Blaya C., Salum G.A., Lima M.S., Leistner-Segal S., Manfro G.G. Lack of association between the Serotonin transporter promoter polymorphism (5-HTTLPR) and panic disorder: a systematic review and meta-analysis. Behav. Brain Funct.: BBF 2007, 3:41.
7. Bryant R.A., Felmingham K.L., Falconer E.M., Pe Benito L., Dobson-Stone C., Pierce K.D., et al. Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol. Psychiatry 2010, 67(12):1217-1219.
8. Caspi A., Hariri A.R., Holmes A., Uher R., Moffitt T.E. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am. J. Psychiatry 2010, 167(5):509-527.
9. Caspi A., Moffitt T.E. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 2006, 7(7):583-590.
10. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301(5631):386-389.
11. Choe A.Y., Kim B., Lee K.S., Lee J.E., Lee J.Y., Choi T.K., et al. Serotonergic genes (5-HTT and HTR1A) and separation life events: gene-by-environment interaction for panic disorder. Neuropsychobiology 2013, 67(4):192-200.
12. 2 challenge in healthy volunteers. Psychopharmacology 2011, 215(4):739-748.
13. Eley T.C., Hudson J.L., Creswell C., Tropeano M., Lester K.J., Cooper P., et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol. Psychiatry 2012, 17(3):236-237.
14. Feinn R., Nellissery M., Kranzler H.R. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am. J. Med. Genet. Part B, Neuropsychiatric Genet.: the official publication Int. Soc. Psychiatr. Genet. 2005, 133B(1):79-84.
15. Fox E., Zougkou K., Ridgewell A., Garner K. The serotonin transporter gene alters sensitivity to attention bias modification: evidence for a plasticity gene. Biol. Psychiatry 2011, 70(11):1049-1054.
16. Goossens L., Sunaert S., Peeters R., Griez E.J., Schruers K.R. Amygdala hyperfunction in phobic fear normalizes after exposure. Biol. Psychiatry 2007, 62(10):1119-1125.
17. Homberg J.R., Lesch K.P. Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 2011, 69(6):513-519.
18. Hudson J.L., Lester K.J., Lewis C.M., Tropeano M., Creswell C., Collier D.A., et al. Predicting outcomes following cognitive behaviour therapy in child anxiety disorders: the influence of genetic, demographic and clinical information. J. Child Psychol. Psychiatry Allied Discip. 2013, 54(10):1086-1094.
19. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 2011, 68(5):444-454.
20. Keers R., Aitchison K.J. Pharmacogenetics of antidepressant response. Exp. Rev. Neurother. 2011, 11(1):101-125.
21. Kim W., Choi Y.H., Yoon K.S., Cho D.Y., Pae C.U., Woo J.M. Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. Prog. Neuro-Psychopharmacol. Biol.l Psychiatry 2006, 30(8):1413-1418.
22. Klauke B., Deckert J., Reif A., Pauli P., Zwanzger P., Baumann C., et al. Serotonin transporter gene and childhood trauma-a GxE effect on anxiety sensitivity. Depress. Anxiety 2011, 28(12):1048-1057.
23. Lester K.J., Hudson J.L., Tropeano M., Creswell C., Collier D.A., Farmer A., et al. Neurotrophic gene polymorphisms and response to psychological therapy. Transl. Psychiatry 2012, 2:e108.
24. Linden D.E. How psychotherapy changes the brain--the contribution of functional neuroimaging. Mol. Psychiatry 2006, 11(6):528-538.
25. Lonsdorf T.B., Kalisch R. A review on experimental and clinical genetic associations studies on fear conditioning, extinction and cognitive-behavioral treatment. Transl. Psychiatry 2011, 1:e41.
26. Lonsdorf T.B., Ruck C., Bergstrom J., Andersson G., Ohman A., Lindefors N., et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010, 10:99.
27. Lonsdorf T.B., Weike A.I., Nikamo P., Schalling M., Hamm A.O., Ohman A. Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. Psychol. Sci. 2009, 20(2):198-206.
28. Marks I.M., Mathews A.M. Brief standard self-rating for phobic patients. Behav. Res. Ther. 1979, 17(3):263-267.
29. Mavissakalian M. Clinically significant improvement in agoraphobia research. Behav. Res. Ther. 1986, 24(3):369-370.
30. Minelli A., Bonvicini C., Scassellati C., Sartori R., Gennarelli M. The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. BMC Psychiatry 2011, 11:50.
31. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry: J.ournal Mental Sci. 1979, 134:382-389.
32. Munafo M.R., Brown S.M., Hariri A.R. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 2008, 63(9):852-857.
33. Pergamin-Hight L., Bakermans-Kranenburg M.J., van Ijzendoorn M.H., Bar-Haim Y. Variations in the promoter region of the serotonin transporter gene and biased attention for emotional information: a meta-analysis. Biol. Psychiatry 2012, 71(4):373-379.
34. Perna G., Favaron E., Di Bella D., Bussi R., Bellodi L. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacol.: official publication of the Am. Coll. Neuropsychopharmacol. 2005, 30(12):2230-2235.
35. Reif A., Richter J., Straube B., Hofler M., Lueken U., Gloster A.T., et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol. Psychiatry 2014, 19(1):122-128.
36. Roffman J.L., Marci C.D., Glick D.M., Dougherty D.D., Rauch S.L. Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol. Med. 2005, 35(10):1385-1398.
37. Roiser J.P., Muller U., Clark L., Sahakian B.J. The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention. International J. Neuropsychopharmacol. / Official Sci. J. Coll. Int. Neuropsychopharmacol. 2007, 10(4):449-461.
38. Roy-Byrne P.P., Craske M.G., Stein M.B., Sullivan G., Bystritsky A., Katon W., et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch. Gen. Psychiatry 2005, 62(3):290-298.
39. Schinka J.A. Measurement scale does moderate the association between the serotonin transporter gene and trait anxiety: comments on Munafo et al. Mol. Psychiatry 2005, 10(10):892-893. (author reply 895-897).
40. Schinka J.A., Busch R.M., Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol. Psychiatry 2004, 9(2):197-202.
41. 2-induced fear by 5-HTTLPR genotype. J. Psychopharmacol. 2011, 25(1):37-42.
42. Schruers K., Griez E. The effects of tryptophan depletion on mood and psychiatric symptoms. J. Affect. Disorders 2003, 74(3):305.
43. 2 provoked panic in panic disorder. J. Psychopharmacol. 2004, 18(4):553-558.
44. Schruers K., Klaassen T., Pols H., Overbeek T., Deutz N.E., Griez E. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res. 2000, 93(3):179-187.
45. Schruers K., van Diest R., Overbeek T., Griez E. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res. 2002, 113(3):237-243.
46. Serretti A., Calati R., Mandelli L., De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr. Drug Targets 2006, 7(12):1659-1669.
47. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):S22-S33. (quiz 34-57).
48. Stein M.B., Schork N.J., Gelernter J. Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacol.: Official Publication Am. Coll Neuropsychopharmacol. 2008, 33(2):312-319.
49. Taylor M.J., Sen S., Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol. Psychiatry 2010, 68(6):536-543.
50. Uher R. The implications of gene-environment interactions in depression: will cause inform cure?. Mol. Psychiatry 2008, 13(12):1070-1078.
51. Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol. Psychiatry 2009, 14(12):1072-1082.
52. Wendland J.R., Martin B.J., Kruse M.R., Lesch K.P., Murphy D.L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol. Psychiatry 2006, 11(3):224-226.
53. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 2001, 50(5):323-330.